Revolution Medicines has begun enrolling patients in RASolute 305, a global Phase 3 clinical trial evaluating zoldonrasib in combination with ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE